Taysha Gene Therapies (TSHA) Stock Forecast & Price Target

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

$2.66

-0.28 (-9.52%)

(As of 04/15/2024 ET)

Taysha Gene Therapies Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 8 Analyst Ratings

Analysts' Consensus Price Target

$6.88
158.46% Upside

High Forecast	$9.00
Average Forecast	$6.88
Low Forecast	$5.00

Type	Current Forecast 4/17/23 to 4/16/24	1 Month Ago 3/18/23 to 3/17/24	3 Months Ago 1/17/23 to 1/17/24	1 Year Ago 4/17/22 to 4/17/23
Consensus Rating	Buy	Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	9 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$6.88	$5.71	$5.38	$8.23
Predicted Upside	158.46% Upside	128.69% Upside	124.53% Upside	441.45% Upside

Get Taysha Gene Therapies Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

TSHA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TSHA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Taysha Gene Therapies Stock vs. The Competition

Type	Taysha Gene Therapies	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.68	2.49
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	158.46% Upside	881.86% Upside	11.20% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
4/11/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00	+122.93%
4/9/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$9.00	+235.82%
3/21/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00	+126.54%
3/21/2024	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$5.00 ➝ $7.00	+136.49%
3/20/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00	+87.27%
3/20/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$7.00	+211.11%
9/20/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$6.00 ➝ $5.00	+62.87%
8/15/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$6.00 ➝ $8.00	+275.59%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:30 AM ET.

TSHA Price Target - Frequently Asked Questions

What is Taysha Gene Therapies's consensus rating and price target?: According to the issued ratings of 8 analysts in the last year, the consensus rating for Taysha Gene Therapies stock is Buy based on the current 8 buy ratings for TSHA. The average twelve-month price prediction for Taysha Gene Therapies is $6.88 with a high price target of $9.00 and a low price target of $5.00. Learn more on TSHA's analyst rating history.
Do Wall Street analysts like Taysha Gene Therapies more than its competitors?: Analysts like Taysha Gene Therapies more than other Medical companies. The consensus rating for Taysha Gene Therapies is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how TSHA compares to other companies.
Does Taysha Gene Therapies's stock price have much upside?: According to analysts, Taysha Gene Therapies's stock has a predicted upside of 150.11% based on their 12-month stock forecasts.

What analysts cover Taysha Gene Therapies?: Taysha Gene Therapies has been rated by Canaccord Genuity Group, Cantor Fitzgerald, Chardan Capital, JMP Securities, Needham & Company LLC, and Piper Sandler in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:TSHA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Taysha Gene Therapies (TSHA) Stock Forecast & Price Target

Taysha Gene Therapies Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

TSHA Analyst Ratings By Month

TSHA Price Targets by Month

Taysha Gene Therapies Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

TSHA Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info